{"id":"NCT03570697","sponsor":"Amgen","briefTitle":"Imaging of Coronary Plaques in Participants Treated With Evolocumab","officialTitle":"High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-19","primaryCompletion":"2020-12-18","completion":"2021-01-21","firstPosted":"2018-06-27","resultsPosted":"2021-11-24","lastUpdate":"2022-05-03"},"enrollment":164,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Coronary Artery Disease (CAD)"],"interventions":[{"type":"DRUG","name":"Evolocumab","otherNames":["Repatha, AMG 145, EvoMab"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Statin therapy","otherNames":[]}],"arms":[{"label":"Evolocumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.","primaryOutcome":{"measure":"Absolute Change From Baseline in Minimum FCT","timeFrame":"Baseline, week 50","effectByArm":[{"arm":"Placebo","deltaMin":21.5,"sd":5.2},{"arm":"Evolocumab","deltaMin":42.7,"sd":5.1}],"pValues":[{"comp":"OG000 vs OG001","p":"0.015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":33,"countries":["United States","Australia","Czechia","Germany","Hungary","Italy","Netherlands"]},"refs":{"pmids":["33708484","33355725","40424182","40020597","35431172"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":81},"commonTop":["Angina pectoris","Myalgia","Hypertension","Diarrhoea","Fatigue"]}}